Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)

Phase Distribution

Ph phase_3
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

terminated3100%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_3

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

NCT01829477
terminatedphase_3

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

NCT01647542
terminatedphase_3

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

NCT01609582

Clinical Trials (3)

Showing 3 of 3 trials
NCT01829477Phase 3

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Terminated
NCT01647542Phase 3

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

Terminated
NCT01609582Phase 3

Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3